Related references
Note: Only part of the references are listed.OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study
C. Dominguez et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
Andrew M. Blumenfeld et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Long-term Treatment Benifits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
Simona Guerzoni et al.
FRONTIERS IN NEUROLOGY (2017)
Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year
I. Aicua-Rapun et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment
Simona Guerzoni et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Update on Medication-Overuse Headache and Its Treatment
Maria Adele Giamberardino et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2015)
Headache disorders are third cause of disability worldwide
Timothy J. Steiner et al.
JOURNAL OF HEADACHE AND PAIN (2015)
Chronic migraine with medication overuse: Association between disability and quality of life measures, and impact of disease on patients' lives
Alberto Raggi et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse
Fayyaz Ahmed et al.
SPRINGERPLUS (2015)
OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study
Andrea Negro et al.
SPRINGERPLUS (2015)
Emerging drugs for migraine treatment
Maria Adele Giamberardino et al.
EXPERT OPINION ON EMERGING DRUGS (2015)
Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: A systematic review
Maria L. Westergaard et al.
CEPHALALGIA (2014)
Prevalence of chronic headache with and without medication overuse: Associations with socioeconomic position and physical and mental health status
Maria Lurenda Westergaard et al.
PAIN (2014)
Medication-overuse headache: epidemiology, diagnosis and treatment
Espen Saxhaug Kristoffersen et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2014)
The International Classification of Headache Disorders, 3rd edition (beta version)
Andre Bes et al.
CEPHALALGIA (2013)
OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline
Stephen D. Silberstein et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Chronic migraine plus medication overuse headache: two entities or not?
Andrea Negro et al.
JOURNAL OF HEADACHE AND PAIN (2011)
Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study
Giorgio Sandrini et al.
JOURNAL OF HEADACHE AND PAIN (2011)
Disability in chronic migraine with medication overuse: Treatment effects through 5 years
F. Andrasik et al.
CEPHALALGIA (2010)
Global prevalence of chronic migraine: A systematic review
J. L. Natoli et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
H. C. Diener et al.
CEPHALALGIA (2010)
Self-help group and medication overuse headache: preliminary data
Elisa Sancisi et al.
NEUROLOGICAL SCIENCES (2009)
Share Paper
